Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma...
In a phase II trial (NRG Oncology/GOG Study 279) reported in the Journal of Clinical Oncology, Horowitz et al found that concurrent cisplatin, gemcitabine...
In the phase II PHERGain trial reported in The Lancet, Pérez-García et al found that a positron-emission tomography (PET)-based, pathologic complete response...
Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation...
In the phase II acelERA BC trial reported in the Journal of Clinical Oncology, Miguel Martín, MD, PhD, and colleagues found that the selective estrogen receptor (ER)...
Immunotherapy following surgery significantly improved disease-free survival compared to placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to results from the international phase III KEYNOTE-564 study presented at the 2021 ASCO Annual Meeting by Toni K....
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
The first overall survival analysis of the WSG-ADAPT HR-/HER2+ study, which evaluated neoadjuvant therapy in patients with hormone receptor (HR)-negative, HER2-positive breast cancer, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or the chemotherapy-free regimen of...
In a retrospective cohort study reported in JAMA Oncology, Erickson et al found that real-world use of targeted therapy after diagnosis of intracranial metastatic disease was associated with improved overall survival vs no use of targeted therapy in patients with HER2-positive breast cancer,...
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, the phase III KEYNOTE-361 trial has shown no significant improvement in progression-free or overall survival with first-line pembrolizumab plus platinum-based chemotherapy vs chemotherapy alone in patients with advanced...
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...